NovaBay Pharmaceuticals Reports Turnaround in Earnings

NovaBay Pharmaceuticals reported a net income of $4.455 million for Q3 2025, marking a turnaround from a $6.011 million loss in 2024. This improvement is due to income from discontinued operations after divesting eyecare and skincare businesses. Despite ongoing operating losses, the company reduced liabilities and is exploring new strategic directions, including blockchain markets, with optimism for future financial stability.

Novabay Pharmac | 10-Q: FY2025 Q3 Revenue: USD 521 K

NovaBay Pharmaceuticals Files Initial Beneficial Ownership Statement for R01 Fund LP

NovaBay Pharmaceuticals Inc. has filed an initial beneficial ownership statement, identifying R01 Fund LP as the beneficial owner. The filing is accessible via the provided link. This news was generated by Public Technologies (PUBT) using AI and is for informational purposes only, not to be considered as financial, investment, or legal advice. The original content was published by NovaBay Pharmaceuticals via EDGAR on October 20, 2025.

NovaBay Pharmaceuticals Regains Compliance With NYSE American Listing Standards

NovaBay Pharmaceuticals Inc. has regained compliance with NYSE American listing standards after addressing deficiencies in stockholders’ equity. The company raised approximately $8.15 million through the sale of pre-funded warrants and Series E non-voting convertible preferred stock, increasing its stockholders’ equity above the required $6 million threshold. The NYSE American has confirmed that all related deficiencies have been resolved.

NovaBay Pharma Announces Leadership Changes and Reverse Stock Split

NovaBay Pharma announced leadership changes and a reverse stock split during its Annual Meeting of Stockholders on October 16, 2025. The stockholders approved a reverse stock split to reduce outstanding shares, affecting voting rights and future issuances. Michael Kazley was appointed as the new CEO and Chairman, while several board members resigned. The company filed to increase its authorized shares, but a proposal to increase preferred stock was rejected. Analysts rate NBY stock as a Hold with a $1.50 price target, reflecting financial challenges despite some positive corporate events.